- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06838273
Une étude de BL-B01D1 en combinaison avec l'osimertinib contre l'osimertinib comme traitement de première intention chez les patients atteints d'un cancer du poumon non à petites cellules avancé ou métastatique non muté par EGFR
Une étude randomisée de phase III de BL-B01D1 en combinaison avec l'osimertinib contre l'osimertinib comme traitement de première ligne chez les patients atteints d'un cancer du poumon non à petites cellules avancé ou métastatique non avancé par EGFR
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Réel)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Chine
- Shanghai East Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Sign the informed consent form voluntarily and follow the protocol requirements;
- Age ≥18 years old;
- Expected survival time ≥3 months;
- Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;
- Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;
- Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;
- At least one measurable lesion meeting the RECIST v1.1 definition was required;
- ECOG 0 or 1;
- The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;
- Urinary protein ≤2+ or < 1000mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;
- Patients with previous systemic therapy;
- Patients had received EGFR-TKI therapy;
- Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;
- History of severe heart disease and cerebrovascular disease;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Were diagnosed with active malignancy within 3 years before randomization;
- Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
- Patients with poor glycemic control;
- A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;
- Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
- Patients with active central nervous system metastasis;
- Had a severe infection within 4 weeks before randomization;
- Patients with massive or symptomatic effusions or poorly controlled effusions;
- Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
- Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
- Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
- Had autologous or allogeneic stem cell transplantation history;
- Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
- A history of severe neurological or psychiatric illness;
- Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
- Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
- Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: BL-B01D1 in Combination with Osimertinib
Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks.
Autres noms:
Oral administration, 80mg daily for a cycle of 3 weeks. |
|
Comparateur actif: Osimertinib
Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Oral administration, 80mg daily for a cycle of 3 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-free survival (PFS)
Délai: Up to approximately 36 months
|
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
Up to approximately 36 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall survival (OS)
Délai: Up to approximately 36 months
|
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death. |
Up to approximately 36 months
|
|
Objective Response Rate (ORR)
Délai: Up to approximately 36 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
Up to approximately 36 months
|
|
Disease Control Rate (DCR)
Délai: Up to approximately 36 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
Up to approximately 36 months
|
|
Duration of Response (DOR)
Délai: Up to approximately 36 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
Up to approximately 36 months
|
|
Treatment Emergent Adverse Event (TEAE)
Délai: Up to approximately 36 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Up to approximately 36 months
|
|
Anti-drug antibody (ADA)
Délai: Up to approximately 36 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated. |
Up to approximately 36 months
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- BL-B01D1-308
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .